MDx Firm Co-Diagnostics Buying Technologies from DNA Logix | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics Co-Diagnostics late on Friday announced an agreement with DNA Logix to acquire certain technologies for genetic analysis in the clinical, industrial, and biothreat spaces.

Sandy, Utah-based Co-Diagnostics will buy DNA Logix's technology pertaining to DNA testing with "superior sensitivity and specificity. The technology facilitates rapid assay development and significantly reduced costs for the end user," it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.